Share This Author
SR141716A is an inverse agonist at the human cannabinoid CB1 receptor.
The perceived effects of smoked cannabis on patients with multiple sclerosis.
The survey findings will aid in the design of a clinical trial of cannabis or cannabinoid administration to MS patients or to other patients with similar signs or symptoms.
Controlled clinical trial of cannabidiol in Huntington's disease
Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice.
Enantiomeric cannabinoids: stereospecificity of psychotropic activity
The 1,1-dimethylheptyl homolog of (−)-(3R,4R)-7-hydroxy-delta-6-tetrahydrocannabinol (compoundII) is highly psychotropic in mice, rats and pigeons. The (+)-(3S,4S) enantiomer (III) was found to be…
Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain.
AM630 antagonism of cannabinoid-stimulated [35S]GTPγS binding in the mouse brain
Brain Cannabinoid Systems as Targets for the Therapy of Neurological Disorders
- P. Consroe
- Biology, MedicineNeurobiology of Disease
- 1 December 1998
These endogenous structures and chemicals and mechanisms are potentially new pathophysiologic substrates, and targets for novel cannabinoid treatments, of several neurological disorders.
delta 9-Tetrahydrocannabinol is a partial agonist of cannabinoid receptors in mouse brain.
Comparison of a new ovine antigen binding fragment (Fab) antivenin for United States Crotalidae with the commercial antivenin for protection against venom-induced lethality in mice.
A novel, affinity-purified, antigen binding fragment (Fab) antivenom (FabAV) for Crotalidae venom poisoning has been produced from the sera of sheep, and the results indicate that FabAV is 3.1-9.6 times more potent than ACP for the prevention of lethality of the nine United States venoms tested.